Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer.
McKenzie J WhiteMadison KolbowSaranya PrathibhaCorinne PraskaJacob S AnkenyChristopher J LaRoccaEric H JensenTodd M TuttleJane Y C HuiSchelomo MarmorPublished in: Breast cancer research and treatment (2023)
Among healthy women with high-RS, ER-positive BC, chemotherapy refusal was associated with decreased OS for women ages 65-79, but did not impact the OS of women ≥ 80 years old. Genomic testing may have limited utility in this population, warranting prudent shared decision-making and further study.
Keyphrases
- estrogen receptor
- positive breast cancer
- polycystic ovary syndrome
- locally advanced
- pregnancy outcomes
- copy number
- breast cancer risk
- cervical cancer screening
- physical activity
- squamous cell carcinoma
- type diabetes
- middle aged
- insulin resistance
- metabolic syndrome
- community dwelling
- dna methylation
- free survival
- genome wide
- adipose tissue